Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer

Catharina J. P. Op ‘t Hoog, Niven Mehra, Benthe van der Weij, Erik Olofsen, Diederik M. Somford, Inge M. van Oort, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter · 2026

Read Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer by Catharina J. P. Op ‘t Hoog, Niven Mehra, Benthe van der Weij, Erik Olofsen, Diederik M. Somford, Inge M. van Oort, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13183711.txt.

Description

Catharina Op t Hoog and co-authors test whether a prostate cancer drug changes morphine exposure in a 2026 study. Enzalutamide is notorious for bending other drugs levels, and morphine is the painkiller of choice partly to dodge that. Twenty-four men with prostate cancer took morphine, half alongside enzalutamide.

Blood curves for morphine matched closely between arms, well inside the no-worry band set in advance. Its active breakdown product ran somewhat higher with the cancer drug aboard. The headline answer reassures prescribers: the preferred painkiller keeps its exposure. Pain control need not be re-engineered around this therapy.

Catalog record

CREATORCatharina J. P. Op ‘t Hoog, Niven Mehra, Benthe van der Weij, Erik Olofsen, Diederik M. Somford, Inge M. van Oort, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13183711

Browse the full library · About the Tower of Babel